| Date | Time | Source | Headline | Symbol | Company |
| 11/23/2021 | 12:15AM | TipRanks | Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA) and Paragon 28 (FNA) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/22/2021 | 4:06PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/22/2021 | 4:01PM | Business Wire | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/19/2021 | 7:00AM | Business Wire | Enanta Pharmaceuticals to Participate in December Investor Conferences | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/18/2021 | 4:01PM | Business Wire | Enanta Pharmaceuticals Announces Update to its Hepatitis B Virus (HBV) Program | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/15/2021 | 4:01PM | Business Wire | Enanta Pharmaceuticals to Host Conference Call on November 22 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/12/2021 | 7:00AM | Business Wire | Enanta Pharmaceuticals Reports Positive Final Data from its Phase 1b Studies of EDP-514, a Novel Hepatitis B Virus Core Inhibitor | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 10/19/2021 | 7:00AM | Business Wire | Enanta Pharmaceuticals Presents New Data for EDP-235, its Lead Oral Protease Inhibitor Designed for the Treatment of COVID-19, at the ISIRV–WHO Virtual Conference 2021 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 10/06/2021 | 8:16AM | Business Wire | New Preclinical Data for EDP-235, Enanta’s Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19, to be Presented at ISRIV-WHO Virtual 2021 Conference: COVID-19, Influenza and RSV: Surveillance-Informed Prevention and Treatment | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 10/05/2021 | 7:00AM | Business Wire | Enanta Pharmaceuticals to Present at the H.C. Wainwright 2nd Annual Hepatitis B Virus Virtual Conference | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 10/04/2021 | 7:00AM | Business Wire | Enanta Pharmaceuticals Provides Update on NASH FXR Agonist Programs | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 10/01/2021 | 7:00AM | Business Wire | Enanta Pharmaceuticals Announces Data Presentations at AASLD’s The Liver Meeting® 2021 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 09/17/2021 | 5:18PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 09/07/2021 | 7:00AM | Business Wire | Enanta Pharmaceuticals to Participate in Investor Conferences in September | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 08/23/2021 | 4:44PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 08/23/2021 | 4:39PM | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 08/23/2021 | 4:02PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 08/23/2021 | 7:00AM | Business Wire | Enanta Pharmaceuticals Elects Yujiro S. Hata to its Board of Directors | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 08/16/2021 | 7:00AM | Business Wire | Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-721, Its Oral Hepatitis B Virus RNA Destabilizer | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 08/09/2021 | 4:05PM | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 08/05/2021 | 4:05PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 08/05/2021 | 4:01PM | Business Wire | Enanta Pharmaceuticals Reports Financial Results for Its Fiscal Third Quarter Ended June 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 08/05/2021 | 7:00AM | Business Wire | Enanta Pharmaceuticals Announces Nomination of Clinical Candidate EDP-235, its Lead Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 07/29/2021 | 7:00AM | Business Wire | Enanta Pharmaceuticals to Host Conference Call on August 5 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2021 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 07/16/2021 | 4:07PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 07/14/2021 | 5:30PM | Business Wire | Enanta Pharmaceuticals Announces the Planned Retirement of Chief Medical Officer Nathalie Adda, M.D. | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 06/23/2021 | 2:01AM | Business Wire | Enanta Pharmaceuticals Presents New Data for EDP-721, an Oral Hepatitis B Virus RNA Destabilizer, at the European Association... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 06/22/2021 | 4:01PM | Business Wire | Enanta Pharmaceuticals Reports Positive Data from Phase 1b Study of EDP-514, a Hepatitis B Virus (HBV) Core Inhibitor, in Vir... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 06/10/2021 | 7:00AM | Business Wire | Enanta Pharmaceuticals to Participate in Two Investor Conferences in June | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 06/03/2021 | 7:00AM | Business Wire | Enanta Pharmaceuticals to Present Preclinical Data for EDP-721, its Novel Oral Hepatitis B Virus RNA Destabilizer, at the Int... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |